Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Practice-Changing Advances in Immuno-Oncology for Non-Small-Cell Lung Cancer
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: July 15, 2021 Expiration: July 14, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Helsinn Healthcare SA
Regeneron Pharmaceuticals, Inc.
Sanofi Genzyme
person default
Mary Jo Fidler, MD
person default
Scott Gettinger, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal first-line immune checkpoint inhibitor and chemotherapy combinations for patients with advanced or metastatic NSCLC
  • Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor–based therapy in NSCLC
  • Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy and in those who are ineligible for surgery or chemoradiation therapy
  • Delineate the current biomarker testing recommendations for patients with stage III and IV NSCLC
  • Incorporate investigational checkpoint inhibitors and clinical trial participation as part of clinical care strategies for NSCLC
  • Appropriately mitigate and manage immune-related adverse events in patients receiving immune checkpoint inhibitors for the treatment of NSCLC

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Mary Jo Fidler, MD

Associate Professor
Hematology-Oncology
Rush University Medical Center
Chicago, Illinois

Mary Jo Fidler, MD, has disclosed that she has received consulting fees from AstraZeneca, BeiGene, G1 Therapeutics, and Jazz and funds for research support from Alkermes, AstraZeneca, Biodesix, Merck, Novartis, Pfizer, and Rakuten Medical.
Scott Gettinger, MD

Professor of Internal Medicine (Medical Oncology)
Chief, Thoracic Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Scott Gettinger, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Genentech/Roche, Iovance, and NextCure.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Shara Pantry, PhD
Shara Pantry, PhD, has no relevant conflicts of interest to report.
Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for medical oncologists and other healthcare providers who treat patients with non-small-cell lung cancer.

Goal

The goal of this program is to improve the knowledge and competence of learners in immuno-oncology for the treatment of non-small cell lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 15, 2021, through July 14, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Practice-Changing Advances in Immuno-Oncology for Non-Small-Cell Lung Cancer
  • CME

Loading...
Watch this on-demand webcast of a live CCO webinar where clinical experts discuss the latest advances in immunotherapy for the management of NSCLC, including discussion of patient cases across disease settings, integration of new data from ASCO 2021, and optimization of therapeutic benefit through management of cancer cachexia syndrome and immune-related adverse events.
person default
Mary Jo Fidler, MD
person default
Scott Gettinger, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: July 15, 2021 Expiration: July 14, 2022

Related Content

Phase I/II trial of mobocertinib for EGFR ex20ins+ advanced NSCLC in cohort of patients with disease progression after initial disease control on EGFR TKI therapy, from WCLC 2021 by Clinical Care Options (CCO)

Released: September 23, 2021

Initial analysis of amivantamab in patients with METex14+ metastatic or unresectable NSCLC from phase I CHRYSALIS trial, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 23, 2021

Downloadable summary slideset from a live CCO Webinar on immunotherapy for the treatment of patients across the spectrum of NSCLC

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 23, 2021

3-year update of CASPIAN showed sustained survival benefit of adding durvalumab to platinum-etoposide for first-line treatment in extensive-stage SCLC, presented at ESMO 2021 and reported by Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 23, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Helsinn Healthcare SA
Regeneron Pharmaceuticals, Inc.
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue